// App-Quantinova.ai

: KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3

Researchers

Presenter

  • Bijal D. Shah

Principal Investigators

  • Olalekan O. Oluwole

  • Aaron C. Logan

  • Maria R. Baer

  • William B. Donnellan

  • Kristen M. ODwyer

  • Houston Holmes

  • Martha L. Arellano

  • Armin Ghobadi

  • John M. Pagel

  • Yi Lin

  • Ryan D. Cassaday

  • Jae H. Park

  • Armen Mardiros

  • Tong Shen

  • Lovely Goyal

  • Remus Vezan

  • Rajul K. Jain

  • William G. Wierda

Medical Centers

  • Moffitt Cancer Center, Tampa, Florida, United States

  • The University of Chicago Medicine, Medicine, Chicago, IL, United States

  • Vanderbilt Ingram Cancer Centre,Nashville,United States

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • University of Maryland Greenebaum Comprehensive Cancer Center,Baltimore,Vereinigte Staaten

  • Sarah Cannon Research Institute, Nashville,United States

  • University of Rochester, Rochester, NY, United States

  • Hematology and Oncology,Baylor Charles A. Sammons Cancer Center,Dallas,United States

  • Winship Cancer Institute of Emory University,Atlanta, GA,Vereinigte Staaten

  • Washington University School of Medicine, Siteman Cancer Center Hematology Labs,St. Louis,United States

  • Swedish Cancer Institute, Seattle, Washington, United States

  • Mayo Clinic, Rochester, United States

  • University of Washington, Fred Hutchinson Cancer Research Center,Seattle, WA,United States

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Kite, a Gilead company ,Santa Monica,United States

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Tocilizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT02614066

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved